BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7930246)

  • 21. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
    Arnout J; Simoons M; de Bono D; Rapold HJ; Collen D; Verstraete M
    J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK).
    Neuhaus KL; von Essen R; Vogt A; Tebbe U; Rustige J; Wagner HJ; Appel KF; Stienen U; König R; Meyer-Sabellek W
    J Am Coll Cardiol; 1994 Jul; 24(1):55-60. PubMed ID: 8006283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of prourokinase injection in patients with ST-elevation myocardial infarction: phase IV clinical trials of the prourokinase phase study.
    Zhao L; Zhao Z; Chen X; Li J; Liu J; Li G;
    Heart Vessels; 2018 May; 33(5):507-512. PubMed ID: 29209778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study.
    Popma JJ; Califf RM; Ellis SG; George BS; Kereiakes DJ; Samaha JK; Worley SJ; Anderson JL; Stump D; Woodlief L
    J Am Coll Cardiol; 1992 Nov; 20(6):1305-12. PubMed ID: 1430679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction--results from the PRIMI trial.
    Ostermann H; Schmitz-Huebner U; Windeler J; Bär F; Meyer J; van de Loo J
    Eur Heart J; 1992 Sep; 13(9):1225-32. PubMed ID: 1396833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase.
    Kasper W; Hohnloser SH; Engler H; Meinertz T; Wilkens J; Roth E; Lang K; Limbourg P; Just H
    J Am Coll Cardiol; 1990 Sep; 16(3):733-8. PubMed ID: 2117622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    J Am Coll Cardiol; 1988 Sep; 12(3):581-7. PubMed ID: 3042835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
    J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical studies with the new glycosylated recombinant prourokinase.
    Sasahara AA; Barker WM; Weaver WD; Hartmann J; Anderson JL; Reddy PS; Villiard EM
    J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):84S-93S. PubMed ID: 8770849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group.
    Lancet; 1989 Apr; 1(8643):863-8. PubMed ID: 2564949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
    Malcolm AD; Keltai M; Walsh MJ
    Eur Heart J; 1996 Oct; 17(10):1522-31. PubMed ID: 8909909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pro-urokinase for infarct therapy].
    Spiecker M; Meyer J
    Herz; 1994 Dec; 19(6):326-35. PubMed ID: 7843689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
    Nordt TK; Moser M; Kohler B; Ruef J; Peter K; Kübler W; Bode C
    Thromb Haemost; 1998 Dec; 80(6):881-6. PubMed ID: 9869154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial.
    Ross AM; Coyne KS; Reiner JS; Greenhouse SW; Fink C; Frey A; Moreyra E; Traboulsi M; Racine N; Riba AL; Thompson MA; Rohrbeck S; Lundergan CF
    J Am Coll Cardiol; 1999 Dec; 34(7):1954-62. PubMed ID: 10588209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).
    Ross AM; Molhoek P; Lundergan C; Knudtson M; Draoui Y; Regalado L; Le Louer V; Bigonzi F; Schwartz W; de Jong E; Coyne K;
    Circulation; 2001 Aug; 104(6):648-52. PubMed ID: 11489769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
    Hsia J; Kleiman N; Aguirre F; Chaitman BR; Roberts R; Ross AM
    J Am Coll Cardiol; 1992 Jul; 20(1):31-5. PubMed ID: 1607535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Incidence of residual thrombi following successful thrombolytic therapy in acute myocardial infarct and their significance for the rate of early re-occlusion. A report of a multicenter dose-finding study for thrombolytic therapy with urokinase preactivated natural prourokinase (TCL 598)].
    Gulba DC; Bode C; Topp J; Höpp HW; Westhoff-Bleck M; Rafflenbeul W; Lichtlen PR
    Z Kardiol; 1990 Apr; 79(4):279-85. PubMed ID: 2113330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.
    White HD; Aylward PE; Frey MJ; Adgey AA; Nair R; Hillis WS; Shalev Y; Brown MA; French JK; Collins R; Maraganore J; Adelman B
    Circulation; 1997 Oct; 96(7):2155-61. PubMed ID: 9337184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.